{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:34:43Z","timestamp":1769175283029,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejim.2025.01.013","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T20:24:05Z","timestamp":1737491045000},"page":"86-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comparative effectiveness of bictegravir versus dolutegravir, raltegravir, and efavirenz-based antiretroviral therapy among treatment-na\u00efve individuals with HIV"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8859-9115","authenticated-orcid":false,"given":"Isaac","family":"N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanink","family":"Caro-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Luis","family":"Mosqueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Pi\u00f1eir\u00faa-Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1290-271X","authenticated-orcid":false,"given":"Anthony A.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2025.01.013_bib0001","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society\u2013USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2025.01.013_bib0002","unstructured":"Gu\u00eda de manejo antirretroviral de las personas con VIH. https:\/\/www.gob.mx\/cms\/uploads\/attachment\/file\/712164\/Gu_a_TAR_fe_erratas_2022.pdf."},{"issue":"16","key":"10.1016\/j.ejim.2025.01.013_bib0003","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 integrase inhibitors: a comparative review of efficacy and safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2025.01.013_bib0004","unstructured":"Alcocer Varela JC. Compra consolidada de medicamentos. Presented at: May 27, 2019. Accessed October 17, 2023. https:\/\/contralinea.com.mx\/\/wp-content\/uploads\/2019\/05\/CPM-SS-medicamentos-27may19.pdf."},{"key":"10.1016\/j.ejim.2025.01.013_bib0005","unstructured":"Reyes-Ter\u00e1n G. Optimizaci\u00f3n de tratamientos: el proyecto de la CCINSHAE. Presented at: February 12, 2020. Accessed October 17, 2023. https:\/\/anmm.org.mx\/actas2020\/SC12FEB2020\/REYES-TERAN.pdf."},{"issue":"11","key":"10.1016\/j.ejim.2025.01.013_bib0006","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1093\/jac\/dkx281","article-title":"HIV pretreatment drug resistance trends in three geographic areas of Mexico","volume":"72","author":"Garc\u00eda-Morales","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"10107","key":"10.1016\/j.ejim.2025.01.013_bib0007","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"The Lancet"},{"issue":"10107","key":"10.1016\/j.ejim.2025.01.013_bib0008","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"Sax","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.ejim.2025.01.013_bib0009","author":"Wang","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejim.2025.01.013_bib0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"10400","key":"10.1016\/j.ejim.2025.01.013_bib0011","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(23)00877-2","article-title":"The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review","volume":"402","author":"Broyles","year":"2023","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.ejim.2025.01.013_bib0012","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ije\/dyz032","article-title":"Accounting for missing data in statistical analyses: multiple imputation is not always the answer","volume":"48","author":"Hughes","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"2","key":"10.1016\/j.ejim.2025.01.013_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0184","article-title":"Assessing missing data assumptions in EHR-based studies: a complex and underappreciated task","volume":"4","author":"Haneuse","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.ejim.2025.01.013_bib0014","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/aje\/kwr302","article-title":"Dealing with missing outcome data in randomized trials and observational studies","volume":"175","author":"Groenwold","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.ejim.2025.01.013_bib0015","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/sim.8471","article-title":"A causal framework for classical statistical estimands in failure-time settings with competing events","volume":"39","author":"Young","year":"2020","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.01.013_bib0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bjid.2020.03.006","article-title":"Profile of drug\u2013drug interactions and impact on the effectiveness of antiretroviral therapy among patients living with HIV followed at an Infectious Diseases Referral Center in Belo Horizonte, Brazil","volume":"24","author":"Pontelo","year":"2020","journal-title":"Braz J Infect Dis"},{"issue":"10","key":"10.1016\/j.ejim.2025.01.013_bib0017","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"issue":"9868","key":"10.1016\/j.ejim.2025.01.013_bib0018","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"The Lancet"},{"issue":"10","key":"10.1016\/j.ejim.2025.01.013_bib0019","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"issue":"9","key":"10.1016\/j.ejim.2025.01.013_bib0020","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz\u2013based regimen for the treatment of HIV-1","volume":"381","year":"2019","journal-title":"N Engl J Med."},{"issue":"19","key":"10.1016\/j.ejim.2025.01.013_bib0021","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejim.2025.01.013_bib0022","doi-asserted-by":"crossref","first-page":"ofae446","DOI":"10.1093\/ofid\/ofae446","article-title":"Comparative effectiveness of switching to bictegravir from dolutegravir-, efavirenz-, or raltegravir-based antiretroviral therapy among individuals with HIV who are virologically suppressed","volume":"11","author":"N\u00fa\u00f1ez","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ejim.2025.01.013_bib0023","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijid.2022.06.041","article-title":"Late-onset opportunistic infections while receiving anti-retroviral therapy in Latin America: burden and risk factors","volume":"122","author":"N\u00fa\u00f1ez","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.ejim.2025.01.013_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195443","article-title":"Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis","volume":"13","author":"Ekrikpo","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ejim.2025.01.013_bib0025","article-title":"Challenges to the HIV care continuum during the COVID-19 pandemic in Mexico: a mixed methods study","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"AIDS Behav"},{"issue":"5","key":"10.1016\/j.ejim.2025.01.013_bib0026","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/apc.2009.0309","article-title":"Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention","volume":"24","author":"Kalichman","year":"2010","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.ejim.2025.01.013_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071108","article-title":"Target trial emulation: applying principles of randomised trials to observational studies","author":"Matthews","year":"2022","journal-title":"BMJ"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T14:21:38Z","timestamp":1740925298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":27,"alternative-id":["S0953620525000238"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.01.013","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of bictegravir versus dolutegravir, raltegravir, and efavirenz-based antiretroviral therapy among treatment-na\u00efve individuals with HIV","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}